Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 188.7% in February

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 146,372 shares, an increase of 188.7% from the January 29th total of 50,692 shares. Based on an average daily volume of 124,954 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.9% of the shares of the company are short sold. Approximately 1.9% of the shares of the company are short sold. Based on an average daily volume of 124,954 shares, the days-to-cover ratio is currently 1.2 days.

Anebulo Pharmaceuticals Stock Performance

Shares of ANEB opened at $0.43 on Thursday. The stock has a market capitalization of $17.47 million, a P/E ratio of -2.25 and a beta of -0.81. Anebulo Pharmaceuticals has a 1 year low of $0.41 and a 1 year high of $3.42. The company’s fifty day moving average is $0.96 and its two-hundred day moving average is $1.92.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its earnings results on Friday, February 13th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.08. Sell-side analysts predict that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

Hedge Funds Weigh In On Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. purchased a new stake in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned approximately 0.12% of Anebulo Pharmaceuticals as of its most recent SEC filing. 28.40% of the stock is currently owned by institutional investors.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.